newsfilter
← Latest News
GlobeNewswire·

DICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent Highlights

Dosed first healthy volunteers in Phase 1 clinical trial of oral IL-17 antagonist S011806 Successfully completed $234.6 million upsized initial public offering SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc.